| Literature DB >> 30710047 |
Shannon M Lange1,2,3, Melanie C McKell1,2,3, Stephanie M Schmidt1,2, Junfang Zhao4, Rebecca R Crowther1,2,3,5, Lisa C Green1,2,6, Rebecca L Bricker1,2, Eusondia Arnett7, S Eleonore Köhler8, Larry S Schlesinger7, Kenneth D R Setchell4, Joseph E Qualls9,2.
Abstract
Immunonutrition as a therapeutic approach is rapidly gaining interest in the fight against infection. Targeting l-arginine metabolism is intriguing, considering this amino acid is the substrate for antimicrobial NO production by macrophages. The importance of l-arginine during infection is supported by the finding that inhibiting its synthesis from its precursor l-citrulline blunts host defense. During the first few weeks following pulmonary mycobacterial infection, we found a drastic increase in l-citrulline in the lung, even though serum concentrations were unaltered. This correlated with increased gene expression of the l-citrulline-generating (i.e., iNOS) and l-citrulline-using (i.e., Ass1) enzymes in key myeloid populations. Eliminating l-arginine synthesis from l-citrulline in myeloid cells via conditional deletion of either Ass1 or Asl resulted in increased Mycobacterium bovis bacillus Calmette-Guérin and Mycobacterium tuberculosis H37Rv burden in the lungs compared with controls. Our data illustrate the necessity of l-citrulline metabolism for myeloid defense against mycobacterial infection and highlight the potential for host-directed therapy against mycobacterial disease targeting this nutrient and/or its metabolic pathway.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30710047 PMCID: PMC6401247 DOI: 10.4049/jimmunol.1801569
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422